The startup specializes in developing CAR-T cell therapies for oncology, utilizing Chimeric Antigen Receptor technology to enhance the immune system's ability to target and eliminate cancer cells. This approach addresses the need for more effective cancer treatments by harnessing the body's own immune response.
Funding
$530K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional autologous T-cell therapies for cancer are complex and time-consuming to manufacture, often resulting in treatment delays for patients with life-threatening diseases. These therapies can also be limited by the quality and availability of a patient's own T-cells.
Solution
Allogenica is developing allogeneic, "off-the-shelf" CAR-T cell therapies designed to be safer, more readily available, and less expensive than current autologous approaches. The company's bioproduction process starts with harvesting stem cells from healthy donors and differentiating them into immature precursor T cells (pre-T cells). These pre-T cells are then engineered with a therapeutic transgene to target and kill cancer cells. The engineered pre-T cells are stored and ready for immediate delivery to patients, eliminating the delays associated with personalized manufacturing. Allogenica's platform aims to provide a less invasive and more accessible alternative to transplants, expanding access to cell therapies for a broader patient population.
Target Audience
The primary target audience includes oncology patients who require CAR-T cell therapy, as well as healthcare providers and institutions seeking more accessible and cost-effective cell therapy options.
Features
- Allogeneic approach using healthy donor stem cells to generate therapeutic T-cells
- Engineered pre-T cells with a unique vector for enhanced anti-cancer activity
- "Off-the-shelf" availability for immediate treatment, bypassing manufacturing delays
- Designed to minimize Graft vs Host Disease (GvHD) through the elimination of TCR expression
- Potential for long-term persistence (over 10 years) and efficient thymic maturation
- High quality start material with great expansion capacity and no exhaustion markers
- Potency assay available for quality control